BMRA — BIOMERICA INC
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 73290 ·
Last close
$2.32
Market Cap
$10.65M
52W High
$3.21
52W Low
$1.45
ADV30
142,180
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| May 2026 | — | — | — | — | — | — | — |
| Feb 2026 | 987,000 | -44,000 | -1,298,000 | -1,312,000 | 4,878,000 | 1,336,000 | 1,561,000 |
| Nov 2025 | 1,210,000 | 51,000 | -1,373,000 | -1,320,000 | 6,034,000 | 2,543,000 | 1,599,000 |
| Aug 2025 | 1,380,000 | 424,000 | -1,118,000 | 2,000 | 6,854,000 | 3,053,000 | 1,699,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,421,000
Investing CF
$-5,000
Financing CF
$2,334,000
CapEx
$-4,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.37
As of
2026-09-06
Balance + Analyst (yfinance extras)
Retained Earnings
$-56,943,000
Inventory
$1,707,000
Receivables
$785,000
ST Investments
—
EBIT TTM
$-5,322,000
Pretax Income TTM
$-3,753,000
Interest Exp TTM
$6,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,453,000
EBITDA
$-5,243,000
Free Cash Flow
$-2,297,000
Enterprise Value
$11,354,288
Total Cash
$1,308,000
Total Debt
$2,383,000
Shares Out
4,588,968
Trailing EPS
$-1.30
Book Value
$0.82
ROE
-112.1%
ROA
-52.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| May 2026 | 4,453,000 | -5,320,000 | -3,775,000 | 6,759,000 | 4,129,000 | 2,630,000 | -3,421,000 |
| May 2025 | 5,311,000 | -5,137,000 | -4,973,000 | 5,945,000 | 1,840,000 | 4,105,000 | -3,842,000 |
| May 2024 | 5,415,000 | -6,367,000 | -5,978,000 | 9,254,000 | 2,663,000 | 6,591,000 | -5,361,000 |
| May 2023 | 5,339,000 | -7,223,000 | -7,140,000 | 14,454,000 | 2,730,000 | 11,724,000 | -5,474,000 |
| May 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.39
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AWHL | Aspira Women's Health Inc. | $12.12M | $0.26 | — |
| QCLS | Q/C TECHNOLOGIES, INC. | $7.11M | $0.87 | — |
| CDIO | Cardio Diagnostics Holdings, Inc. | $5.77M | $1.95 | — |
| TRIB | TRINITY BIOTECH PLC | $5.50M | $6.76 | — |
| VNRX | VOLITIONRX LTD | $4.91M | $0.26 | — |
News headlines (Yahoo Finance, 1h cache)
Biomerica Reports Fiscal 2026 Year-End Financial Results
2026-09-01 12:19 · Yahoo
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
2026-05-28 12:19 · Yahoo
Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
2026-04-29 12:19 · Yahoo
Biomerica Reports Third Quarter Fiscal 2026 Financial Results
2026-04-13 22:57 · Yahoo
Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
2026-04-14 12:19 · Yahoo
Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
2026-04-16 12:19 · Yahoo
Biomerica Announces $2.23 Million Financing
2026-08-27 12:19 · Yahoo
Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
2026-03-18 12:19 · Yahoo
Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
2026-03-05 13:19 · Yahoo
Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
2026-02-26 13:19 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.